Freedom to Heal Act of 2025
Analysis under review: This bill has generated analysis that may be too generic or incomplete. Clause-level evidence remains available below.
Summary
What This Bill Does
This bill directs the Attorney General to create a special registration process allowing physicians to directly administer certain schedule I investigational drugs to eligible patients under the federal right-to-try framework.
Who Benefits and How
Eligible patients and their physicians could gain a structured route to use certain schedule I investigational drugs under right-to-try rules.
Who Bears the Burden and How
The Department of Justice would need to process special registrations, set diversion controls, accept electronic filings, and issue interim and final rules, while participating physicians would face new application, storage, and recordkeeping requirements.
Key Provisions
- Creates a special registration process for physicians to directly administer schedule I eligible investigational drugs to eligible patients under right-to-try rules.
- Sets application, approval, electronic submission, possession, security, inspection, and notification requirements for registered physicians.
- Requires interim and final rules to prevent diversion and implement the new registration framework.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers.
At a Glance
What This Bill Does
This bill directs the Attorney General to create a special registration process allowing physicians to directly administer certain schedule I investigational drugs to eligible patients under the federal right-to-try framework.
Key Policy Areas
Healthcare, Government Administration
Primary Purpose
This bill directs the Attorney General to create a special registration process allowing physicians to directly administer certain schedule I investigational drugs to eligible patients under the federal right-to-try framework.
Policy Domains
Main Provisions
Identified Gains
Contextual inference, no direct clause citation- Eligible patients and physicians seeking controlled access to schedule I investigational drugs under right to try
Contextual inference, no direct clause citation
Identified Costs
Contextual inference, no direct clause citation- Justice Department officials and participating physicians implementing the special-registration regime
Contextual inference, no direct clause citation
Sponsors
Legislative Progress
In CommitteeMr. Booker (for himself and Mr. Paul) introduced the following …
Read twice and referred to the Committee on the Judiciary.
Introduced in Senate
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
Physicians and eligible patients seeking access to schedule I investigational drugs under right to try
Justice Department officials responsible for processing registrations, preventing diversion, and issuing rules
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "the_attorney_general"
- → Attorney General
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology